Nordic Nanovector to present at 3rd Targeted Radiopharmaceutical Summit 2021
Oslo, Norway, 7 December 2021 Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases announces that its Chief Scientific Officer, Jostein Dahle, will give a presentation on 8 December at the 3rd Targeted Radiopharmaceutical Summit 2021 event (7-9 December 2021). The presentation slides will be available on 8 December at 17:00 CET at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentations. Presentation details are as follows: